Cocrystal Pharma Inc. Common Stock (COCP)

About COCP

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV)…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

10

Website

www.cocrystalpharma.com/

Fundamentals

1-day range

$1.1$1.18

Market cap

$12.96M

P/E (trailing)

—

P/E (forward)

-1.90

EPS (trailing)

$-0.73

Dividend yield

—

Beta

1.52

Avg. volume

71.7K

Dividend pay date

January 24, 2018

Forecasts

2 analyst ratings

Cocrystal Pharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• COCP

  Cocrystal Pharma Inc. Common Stock

  $1.11

  ▼ 2.63%
  Market cap $12.96MP/E —
  $0.76$2.67
• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $12.88MP/E Infinity
  $3.02$49.6
• PHIO

  Phio Pharmaceuticals Corp. Common Stock

  $1.13

  ▲ 0.45%
  Market cap $11.97MP/E —
  $0.8127$4.19
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31
• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.92MP/E —
  $0.281$2.06
• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $15.11MP/E —
  $1.03$8.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Watching Cocrystal Pharma; Zacks Small-Cap Research Gives Stock $8 Price Valuation
  benzinga · 8/20/2026
• Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
  Benzinga · 8/13/2026
• Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b Data
  Benzinga · 8/3/2026

• Phillip Frost, MD, et al. · August 5, 2026 · Buy

  10.0K @ $0.9816
• Phillip Frost, MD, et al. · August 3, 2026 · Buy

  75.0K @ $0.9412
• James Sapirstein · June 3, 2026 · Grant

  235.0K

Institutional Ownership

March 31, 2026

Total shares held

752.2K

Total value held

$746.5K

Institutional holders

25